Purpose: To investigate the long-term effects of topical latanoprost 0.005% treatment on pupillary functions in early-stage primary open-angle glaucoma (POAG) eyes using automated pupillometry.
Methods: This prospective study involved 20 eyes of 20 treatment-naive subjects with early-stage POAG. After comprehensive ophthalmic examination, static and dynamic pupillometry measurements were performedbefore treatment, at the 1st follow-up visit (1.10 ± 0.30 months) and the 2nd follow-up visit (25.85 ± 10.26 months) after treatment initiation. Dynamic parameters included resting diameter (mm), amplitude (mm), latency (ms), duration (ms), and velocity (mm/s) of pupil contraction and dilation. Static pupillometry parameters were pupil diameter (PD, mm) in high-photopic, low-photopic, mesopic and scotopic conditions.
Results: The velocity of pupil dilation significantly decreased during the 1st visit ( = 0.008) and the 2nd visit ( = 0.0003) of treatment compared to the pre-treatment visit. The resting PD was also significantly higher after the 1st visit ( = 0.003) and the 2nd visit ( = 0.001) compared to the pre-treatment visit. However, the difference in resting PD measured between the 1st and 2nd visits did not reach statistical significance ( = 0.065). There were no significant changes in other dynamic parameters ( > 0.05 for all). Additionally, a mild, but not significant, mydriatic effect was observed in PD measurements under scotopic, mesopic and low photopic lighting conditions after follow-up. None of the static and dynamic parameters correlate with age, changes in intraocular pressure (IOP) or mean deviation (MD) values of visual field tests.
Conclusion: The long-term topical latanoprost 0.005% treatment in early-stage POAG has a slight mydriatic effect on the pupil. Further longitudinal clinical studies with larger patient cohorts are necessary to better understand the effects of latanoprost on pupillary functions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/11206721241227780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.
BMC Ophthalmol
December 2024
Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Background: Prostaglandin analogs are first-line treatments for open-angle glaucoma due to their proven efficacy in reducing intraocular pressure. Despite their topical administration, systemic adverse drug Events (ADEs) have been reported. This study investigates the systemic ADEs associated with topical prostaglandin analogs using the United States Food and Drug Administration (USFDA) Adverse Drug Event Reporting System (AERS) database.
View Article and Find Full Text PDFChanges in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
- Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
- Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.
Vet Ophthalmol
November 2024
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Objective: To evaluate the effects of latanoprostene bunod on intraocular pressure (IOP) and pupil diameter (PD) in normal cats and cats with feline congenital glaucoma (FCG).
Animals Studied: Five normal and 5 FCG cats.
Procedures: This masked, controlled crossover study comprised a 1-day Pre-treatment phase followed by two 10-day Treatment phases, each followed by a 10-day Recovery phase.
TH07 - A New Novel Topical Treatment for Androgenic Alopecia.
Int J Trichology
October 2024
Triple Hair Inc., Canada.
Objectives: Androgenic alopecia (AGA) is common among men. Currently, topical minoxidil and oral finasteride are approved by the FDA for the treatment of AGA. Unfortunately, neither of them is completely effective and systemic adverse events have been reported after finasteride administration.
View Article and Find Full Text PDFSelf-assembled latanoprost loaded soluplus nanomicelles as an ophthalmic drug delivery system for the management of glaucoma.
Sci Rep
November 2024
Department of Pharmacy, University of Peshawar, Peshawar, 25000, Pakistan.
Glaucoma, a leading cause of blindness due to elevated intraocular pressure (IOP), is managed with medications like latanoprost (LAT), a prostaglandin analogue, to enhance aqueous outflow. Despite the challenge posed by eye anatomy and tear dynamics, effective ocular bioavailability via topical administration remains elusive. This study aims to optimize self-assembled nanomicelles incorporating LAT, an anti-glaucoma drug, belonging to BCS Class II (low solubility and high permeability) via a two-level, two-factor full factorial design, the nanomicelles were formulated via direct dissolution method and validated using design of expert.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!